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The effect of a synthetic pentnsaechetide that specil'w.ally causes the inactivation of [actor Xa on the development of 
wothrombinase activity in human plasma was monitared using four triggers of coagulation: (a) human brain thrombo- 
plnstin; (b) contact activation; (c) factor X activating enzyme complex; (d) prothrombln activating enzyme complex. 
lnln'bition was similar with the triggers a, b and c. With wothrombinase (d), the inhibition strongly decreased with 
increasing amounts of fr ctor Va present. This indicates !hat only free factor Xa is inhibited. Because both the intrinsic 
pathway (b) and the extrinsic pathway (a) are inhibited by the pentasaecharide, we conclude that free factor Xa plays a 
rate-limiting role in the pathways, so timt there is no reason to postulate the existance of 'suparcomplexes' consisting of 
factors IXa, Vllla, X(a), Va and prothrombin adsorbed on the same pbosphnllpid particle (intrinsic system) or factor 
VII(a), X(a), Va ~_'~ prothrombin adsorbed on tissue thromboplastin (extrinsic system). 
The series of procnzyme-enzyme conversions that 
leads to prothrombin activation differs according to the 
uigger used to start the dotting of blood. With an 
excess of tissue factor (TF) present, a large amount of 
the factor VII-TF complex forms which activates factor 
X. Factor Xa then converts prothrombin (factor II) into 
thrombin (factor Ila). If  there is no tissue factor present 
the blood coagulation system can be activated by glass, 
kaolin etc. In that case factor XIa will appear, which 
activates factor IX. Factor IXa then activates factor X 
which, once activated, activates prothrombin. When 
smell amounts of TF are present, which is probably the 
more physiological situation, then not only direct 
activation of factor X by factor VII-TF plays a role but 
also indirect activation that occurs because factor VII- 
TF  activates factor IX that then activates factor X 
11-5]. 
Neither factor IXa nor factor Xa is an efficient 
enzyme when acting alone. They both need to he 
adsorbed onto a phospholipid surface and next to a 
protein co[actor in order to obtain a physiologically 
important activity [6-9]. The co[actor for factor IXa is 
factor VlIIa; that for factor Xa is factor Va. Both these 
Abbreviation: IF, tissue factor. 
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factors arise from their plasmatic precursors forms by 
the action of thrombin [101. 
Both factor IXa and factor Xa act when adsorbed on 
a phospholipid surface. It therefore is conceivable tha~ 
the actual formation of thrombin in plasma occurs at 
that surface in a cluster of factors IXa, Villa X(a), Va 
and II in which factor X first plays the role of substrate 
to factor IXa and, once activated acts as the enzyme 
that activates prothrombin. Indeed, it has been sug- 
gested that ' the reactions of the procoagulant cascade 
may involve sequential channeling of reaction products 
between enzyme complexes on the same cell surface" 
[11,12]. Alternatively, factor Xa may dissociate from the 
lipid once it is formed and from free solution form the 
factor II activating complex by adsorption next to fac- 
tor Va onto phospholipid. Analogously in the extrinsic 
system either a 'supercomplex' may form on the lipo- 
protein TF when not only factor VII(a) adsorbs there, 
but also factors X(a), Va and prothrombin. Alterna- 
tively, TF-VIi(a) may be the enzymatic entity that 
produces free Xa, which then, with factor Va and phos- 
pholipid, forms prothrombinase as in the intrinsic sys- 
tem. 
Factor Va is known to enhance the binding of factor 
Xa to phospholipid more than 1000-fold [13,14]. One 
can therefore suppose that the first of the two mecha- 
nisms mentioned above would be operative if factor Va 
were present in the immediate vicinity of factor X at the 
moment it was activated. At this moment it is corn- 
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pletely unknown which of the two possible mechanisms 
is operative under physiological conditions. 
In ordei" to decide between these alternatives we 
measured the time-course of the prothrombinase activ- 
ity in clotting blood under a variety of conditions. The 
prothrombinase activity as a function of time was ob- 
tained from the thrombin generation curve by a recently 
developed method [15]. As a first step we determined 
two pseudo-first-order breakdown constants of thrum- 
bin in plasma: k], which governs the inactivation of 
thrombin by AT IlI and minor irthibitors, and k2, 
which determines the formation of the a z macro- 
globufin-thrombin complex. Then the time-course of 
thrombin generation is assessed at 10-30 s intervals by 
subsampling into a solution of the thrombin-specific 
chromogenic substrate $2238 (HD-phe-pip-arg-pNA). 
At every measuring point the velocity of prothrombin 
conversion, i.e., the prothrombinase activity, is calcu- 
lated as the sum of the experimental thrombin genera- 
tion velocity and the breakdown velocity calculated 
from the thrombin concentration at that moment and 
the breakdown constants. The complications which arise 
from the fact that the thrombin-a2M complex has a 
persistent amidolytic activity, is accounted for [15]. 
As a tool in these experiments we used the synthetic 
pentasaceharide that represents the AT III binding site 
of heparin [16]. This substance markedly enhances the 
inactivation of factor Xa by AT III but does not in- 
fluence the breakdown of thrombin activity [17]. 
In a first series of experiments we determined the 
inhibition by pentasaeeharide of the peak pro- 
thrombinase activity that was elicited by tissue 
thromboplastin or by contact activation (Fig. l a  and b). 
The inhibition observed was similar in both cases. We 
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Fig. L The inhibition of peak prothrombinase activity by penlasac- 
charide. Reaction mixture: 240 FI ¢ilrated plasma; 60 pl pentasac- 
-haride solution in 50 mM Tris-HCI/100 mM NaCI (pH 7.35); 60 FI 
trigger solution. At 10 s intervals 10/~1 was subsampled into 20 #M 
$2238 in 50 mM Tris-HCI (pH 7.9)/100 mM NaO/20 mM EDTA. 
The thrornbin concentration was determined from dO/dr measured 
at 405 nM. (Full details on the method in Ref. 15. The followii]g 
triggers were used: (a) o, human brain thromboplastin diluted l : 40; 
(b) e, kaolin, 25 ixg/ml and phospholipid 1 ~M; (c) 4. complete 
tenas¢ (factor Villa. factor lXa. PL); (d) A, tenase without factor 
Villa; (e) O. complete prothrombinas¢ (factor Va, factor Xa, PL). 
too 
75 
g SO 
25 
~ c  
o t 
0.00'2 0.010 0.110a t.doo lO.OOo 
Factor V¢ (aM) (log .coge) 
Fig. 2. The factor Va dependency of the inhibiticda by pentasacchafide 
of factor Xa,induced prothrombinase activity. Reaetioi~ mixture: see 
Fig. 1. Pentasaccharide concemradon: 5 nM. 
then prepared a trigger solution of factor-X-activating 
enzyme (tenase) by adding together (5 nM) factor 1Xa, 
(2 riM) factor VlIIa and (12 /~M) phospholipid in 
CaCI2. The phosphofipid used was a 20/80% mixture of 
phosphatidylserine and phosphatidylcholine. For fur- 
ther details and the preparation of the purified factors 
see legend to Fig. 1 and Ref. 18. At zero time, 60 lal of 
this mixture was , '-:~ to trigger thrombin formation, 
thus shortcutting tk.. (actor-lXoactivating reactions. The 
inhibition was similar to that seen in the previous setups 
(Fig. lc). Omitting factor Vil la  from the activation 
mixture did not influence the degree of inhibition by 
pentasaccharide (Fig. lc  and d). When, however, 
thrombin formation was triggered by a solution of the 
prothrombin-activating enzyme (i.e., factor Xa (2 nM), 
factor Va (12 nM), phosphofipid (12 tiM), CaCI2 (5 
mM), no inhibition was observed (Fig. le). 
In Fig. 2 it is seen that the inhibition by pentasac- 
charide of the peak prothromhinase activit) in plasma is 
dependent upon the amount of factor Va present. At 
h i ~  factor Va concentrations the inl~ihition is negligi- 
ble, whereas it increases with decreasing factor Va con- 
centration. 
As mentioned above, factor Va fosters the binding of 
factor Xa to the phosphofipid surface. The K s of factor 
Xa and the phospholipid mixture used in these experi- 
ments is about 10 -6 M in the absence of factor Va and 
about 10 -It  M in presence of an excess of factor Va 
[13,14]. The concentration of factor Va in our experi- 
ments therefore determines the amount of factor Xa 
bound to the phosphofipids. That the pentasaccharide 
does not inhibit at high factor 'Ca concentrations there- 
fore means that is does not inhibit factor Xa bound to 
phospholipid and factor Va. Because the pentasac- 
charide does inhibit thrombin formation in plasma that 
is triggered by either tissue factor or by contact activa- 
tion, it may be concluded that under these cir- 
cumstances a rate hiinting amount of factor Xa occurs 
in free form. Consequently, free factor Xa must be on 
the main pathway of thrombin generation in plasma 
u n d e r  o u r  exper imenta l  condi t ions ,  an d  there is n o  
reason  to assume tha t  there is a close in teract ion be-  
tween the factor  IXa  - Fac to r  V i l l a  complex  ( intr insic  
sys tem) or  the  factor  VI I ( a ) -TF  complex  (extrinsic sys- 
tem) and  the p ro th rombinase  complex  o n  the  same  
surface when  ei ther  h u m a n  b ra in  t h rombop la s t i n  or  
phospho l ip id  vesicles are used  as  a source  of  phospho-  
l ipid.  
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